AK112
AssetAntibody
Bispecific antibody targeting PD-1 and VEGF
- Stage
- Phase 3
- Modality
- Antibody
- Target
- VEGFA
- Indications
- 5
- Trials
- 1,991
- Developers
- 1
Indications
5Biliary tract cancer
Phase 3ACTIVE_NOT_RECRUITINGNCT06591520clinicaltrials.gov7 Oct 2026
Cervical cancer
Phase 3ACTIVE_NOT_RECRUITINGNCT04982237clinicaltrials.gov7 Oct 2026
Locally advanced cervical carcinoma
Phase 3ACTIVE_NOT_RECRUITINGNCT05235516clinicaltrials.gov7 Oct 2026
2 more
- Targets and what it contains3
- Owner and partners1
- Trials1,991
- Evidence for its targets3
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 6 sources